Maroto-Montero José M, Portuondo-Maseda M Teresa, Lozano-Suárez Maximino, Allona Antonio, de Pablo-Zarzosa Carmen, Morales-Durán María D, Muriel-Garcia Alfonso, Royuela-Vicente Ana
Unidad de Rehabilitación Cardiaca, Servicio de Cardiología, Hospital Ramón y Cajal, Madrid, Spain.
Rev Esp Cardiol. 2008 Sep;61(9):917-22.
Erectile dysfunction is common in patients with coronary heart disease. The aim of this study was to investigate the incidence of, etiological factors associated with, and treatment results obtained in this condition in patients participating in a cardiac rehabilitation program.
The study included 420 male patients with heart disease who were taking part in a multicomponent therapeutic program that involved physical exercise, psychological techniques and risk factor reduction.
Overall, erectile dysfunction was present in 216 patients (52.6%) and there were clear associations with age (P< .001), diabetes mellitus (P< .001), arterial hypertension (P=.029), cigarette smoking (P=.044) and treatment with angiotensin-converting enzyme inhibitors (P=.003) and diuretics (P< .001). However, there were no links to treatment with beta-blockers, calcium antagonists, statins or antiplatelet agents. There were direct associations with trait anxiety (P=.009) and state anxiety (P=.006) and with depression (P=.003). The final multivariate analysis model included diabetes mellitus, smoking, diuretic use, state anxiety and age as significant variables. Only 59 patients agreed to treatment with a phosphodiesterase-5 inhibitor, with positive results in 45 (76.27%). Treatment was contraindicated in 41 patients because they were taking nitrates for myocardial ischemia. The remaining patients expressed no interest, had relationship problems or were worried about complications.
The incidence of erectile dysfunction was substantial. The condition was directly associated with risk factors for atherosclerosis, treatment, and psychological disorders (i.e., anxiety and depression). Relationship problems and the fear of complications may explain why many patients refused to take phosphodiesterase-5 inhibitors.
勃起功能障碍在冠心病患者中很常见。本研究旨在调查参与心脏康复计划的患者中这种情况的发生率、相关病因及治疗结果。
该研究纳入了420名患有心脏病的男性患者,他们参与了一个多组分治疗计划,包括体育锻炼、心理技术和危险因素降低。
总体而言,216名患者(52.6%)存在勃起功能障碍,且与年龄(P<0.001)、糖尿病(P<0.001)、动脉高血压(P = 0.029)、吸烟(P = 0.044)以及使用血管紧张素转换酶抑制剂(P = 0.003)和利尿剂(P<0.001)有明显关联。然而,与使用β受体阻滞剂、钙拮抗剂、他汀类药物或抗血小板药物无关联。与特质焦虑(P = 0.009)、状态焦虑(P = 0.006)以及抑郁(P = 0.003)有直接关联。最终的多变量分析模型将糖尿病、吸烟、利尿剂使用、状态焦虑和年龄作为显著变量。只有59名患者同意使用磷酸二酯酶-5抑制剂治疗,其中45名(76.27%)效果良好。41名患者因正在服用硝酸酯类药物治疗心肌缺血而禁忌使用该药物。其余患者表示不感兴趣、存在关系问题或担心并发症。
勃起功能障碍的发生率很高。该情况与动脉粥样硬化的危险因素、治疗以及心理障碍(即焦虑和抑郁)直接相关。关系问题和对并发症的恐惧可能解释了为什么许多患者拒绝服用磷酸二酯酶-5抑制剂。